Gland Pharma on Friday posted a 58.29 per cent rise in consolidated net profit to Rs 290.75 crore in the September quarter, driven by strong execution across businesses. The company had reported a net profit of Rs 183.68 crore in the year-ago period. The pharmaceutical company's revenue from operations rose to Rs 1,833.58 crore in the quarter under review from Rs 1,486.87 crore a year ago, the company said in a regulatory filing. Total expenses also rose to Rs 1,471.69 crore in the July-September period from Rs 1,287.12 crore a year earlier, it said. The company launched four molecules -- Sugammadex, Erythromycin, Fluorouracil and Atropine sulfate -- in the US this quarter, it said in a release. Gland Pharma Executive Chairman Srinivas Sadu said, "We delivered another quarter of strong growth...driven by strong execution across our businesses. Our CDMO business grew 31 per cent year-on-year, supported by expanding customer engagements, strategic partnerships and a robust opportuni
Hence then, the article about gland pharma q2fy27 results net profit rises 58 to 290 75 crore was published today ( ) and is available onBusiness Standard ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( Gland Pharma Q2FY27 results: Net profit rises 58% to ₹290.75 crore )